Peripheral Blood Mononuclear Cells Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Cryopreserved or Frozen PBMC, Cultured or Fresh PBMC, and Peripheral Blood Mononuclear Cell Isolation & Viability Kits), By Application (Immunology, Hematology, Infectious Disease, Hematology, and Others), By Techniques (Density Gradient Centrifugation, Leukapheresis, and Others), By Source (Human, Animals), By Region and Competition, 2020-2030F
Market Overview
Global Peripheral Blood Mononuclear Cells Market was valued at USD 280.89 million in 2024 and is expected to reach USD 496.02 million by 2030 with a CAGR of 10.02% during the forecast period. The global market for Peripheral Blood Mononuclear Cells is experiencing significant growth, driven by the rising rate in number of cell therapies, high demand of research and development for toxicology testing and reaction mechanism of the compound responsible for new and stable development of products. For instance, in June 2023, a study published in National Library of Medicine, it assessed the immune response of peripheral blood mononuclear cells (PBMC) that were infected in vitro with the Colombian strain (Col) of Trypanosoma cruzi and treated with Benzonidazole.
Key Market Drivers
Government-Funded Cell Therapy and Immunology Research
Governments worldwide are significantly increasing investments in cell and gene therapy, where PBMCs play a critical role. In the U.S., the National Institutes of Health (NIH)?continues to back programs—such as immuno-oncology and vaccine research—that rely heavily on PBMC-based assays to characterize immune responses before and after experimental treatments. NIH-funded vaccine programs studying T-cell immunity routinely isolate PBMCs from donors to quantify immunogenicity in clinical testing. Similarly, in Europe, the Innovative Medicines Initiative (IMI)—a €2?billion public–private partnership co-funded by the European Commission—supports drug development platforms that use PBMC-based biomarker identification and immune monitoring in early-phase clinical trials. This large-scale public-sector support for PBMC-integrated therapeutics research underlines PBMCs’ indispensable role in translational medicine and offers a robust, policy-backed driver for market expansion.
Key Market Challenges
Regulatory and Quality Compliance Complexity
A significant challenge arises from the stringent and fragmented regulatory frameworks governing PBMC collection, processing, and distribution across jurisdictions. In the European Union, PBMC isolation facilities must conform to EU Tissue and Cells Directives (EUTCD) as well as national regulatory agency audits (e.g., Germany’s Paul-Ehrlich-Institut), with repeat compliance checks and data privacy enforcement under GDPR—violations can incur fines exceeding €20?million. In China, PBMC processing kits are treated as Class III medical devices requiring clinical validation, and export of PBMC samples with human genetic information is restricted under the 2021 Biosecurity Law, mandating dual approvals from NMPA and the Ministry of Commerce. These variable, complex regulations raise costs for cross-border research and discourage adoption in regions without harmonized oversight, inhibiting global standardization and scalable PBMC usage.
Key Market Trends
Expanding Role in Vaccine Development and Immuno-Monitoring
A rapidly emerging trend is the expanded application of PBMCs for vaccine research and immunogenicity evaluation, especially in government-backed vaccine rollouts and pandemic preparedness. PBMCs offer critical insight into T-cell responses, cytokine profiles, and durability of immune memory. Governments funding large-scale vaccine trials—for diseases like COVID-19, malaria, tuberculosis—routinely incorporate PBMC-based assays into protocols to evaluate safety and immune efficacy. This creates predictable public-sector demand for standardized PBMC isolation, storage, and testing services, accelerating market growth tied to national immunization programs.
Key Market Players
Report Scope:
In this report, the Global Peripheral Blood Mononuclear Cells Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Competitive Landscape
Company Profiles: Detailed analysis of the major companies presents in the Global Peripheral Blood Mononuclear Cells Market.
Available Customizations:
Global Peripheral Blood Mononuclear Cells Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Global Peripheral Blood Mononuclear Cells Market was valued at USD 280.89 million in 2024 and is expected to reach USD 496.02 million by 2030 with a CAGR of 10.02% during the forecast period. The global market for Peripheral Blood Mononuclear Cells is experiencing significant growth, driven by the rising rate in number of cell therapies, high demand of research and development for toxicology testing and reaction mechanism of the compound responsible for new and stable development of products. For instance, in June 2023, a study published in National Library of Medicine, it assessed the immune response of peripheral blood mononuclear cells (PBMC) that were infected in vitro with the Colombian strain (Col) of Trypanosoma cruzi and treated with Benzonidazole.
Key Market Drivers
Government-Funded Cell Therapy and Immunology Research
Governments worldwide are significantly increasing investments in cell and gene therapy, where PBMCs play a critical role. In the U.S., the National Institutes of Health (NIH)?continues to back programs—such as immuno-oncology and vaccine research—that rely heavily on PBMC-based assays to characterize immune responses before and after experimental treatments. NIH-funded vaccine programs studying T-cell immunity routinely isolate PBMCs from donors to quantify immunogenicity in clinical testing. Similarly, in Europe, the Innovative Medicines Initiative (IMI)—a €2?billion public–private partnership co-funded by the European Commission—supports drug development platforms that use PBMC-based biomarker identification and immune monitoring in early-phase clinical trials. This large-scale public-sector support for PBMC-integrated therapeutics research underlines PBMCs’ indispensable role in translational medicine and offers a robust, policy-backed driver for market expansion.
Key Market Challenges
Regulatory and Quality Compliance Complexity
A significant challenge arises from the stringent and fragmented regulatory frameworks governing PBMC collection, processing, and distribution across jurisdictions. In the European Union, PBMC isolation facilities must conform to EU Tissue and Cells Directives (EUTCD) as well as national regulatory agency audits (e.g., Germany’s Paul-Ehrlich-Institut), with repeat compliance checks and data privacy enforcement under GDPR—violations can incur fines exceeding €20?million. In China, PBMC processing kits are treated as Class III medical devices requiring clinical validation, and export of PBMC samples with human genetic information is restricted under the 2021 Biosecurity Law, mandating dual approvals from NMPA and the Ministry of Commerce. These variable, complex regulations raise costs for cross-border research and discourage adoption in regions without harmonized oversight, inhibiting global standardization and scalable PBMC usage.
Key Market Trends
Expanding Role in Vaccine Development and Immuno-Monitoring
A rapidly emerging trend is the expanded application of PBMCs for vaccine research and immunogenicity evaluation, especially in government-backed vaccine rollouts and pandemic preparedness. PBMCs offer critical insight into T-cell responses, cytokine profiles, and durability of immune memory. Governments funding large-scale vaccine trials—for diseases like COVID-19, malaria, tuberculosis—routinely incorporate PBMC-based assays into protocols to evaluate safety and immune efficacy. This creates predictable public-sector demand for standardized PBMC isolation, storage, and testing services, accelerating market growth tied to national immunization programs.
Key Market Players
- Charles River Laboratories International, Inc.
- Lonza Group AG
- Corning Inc.
- Bio-Rad Laboratories Inc.
- ABCAM
- Biolegend Inc.
- ZEN-Bio Inc.
- DAPCEL, Inc.
- Creative Bioarray
- iXCells Biotechnologies USA, LLC
Report Scope:
In this report, the Global Peripheral Blood Mononuclear Cells Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- Peripheral Blood Mononuclear Cells Market, By Product:
- Cryopreserved or Frozen PBMC
- Cultured or Fresh PBMC
- Peripheral Blood Mononuclear Cell Isolation & Viability Kits
- Peripheral Blood Mononuclear Cells Market, By Application:
- Immunology
- Infectious Disease
- Hematology
- Others
- Peripheral Blood Mononuclear Cells Market, By Technique:
- Density Gradient Centrifugation Process
- Leukapheresis
- Peripheral Blood Mononuclear Cells Market, By Source:
- Human
- Animals
- Peripheral Blood Mononuclear Cells Market, By Region:
- North America
- United States
- Mexico
- Canada
- Europe
- France
- Germany
- United Kingdom
- Italy
- Spain
- Asia-Pacific
- China
- India
- South Korea
- Japan
- Australia
- South America
- Brazil
- Argentina
- Colombia
- Middle East and Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies presents in the Global Peripheral Blood Mononuclear Cells Market.
Available Customizations:
Global Peripheral Blood Mononuclear Cells Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, and Trends
4. IMPACT OF COVID-19 ON GLOBAL PERIPHERAL BLOOD MONONUCLEAR CELLS MARKET
5. VOICE OF CUSTOMER
6. GLOBAL PERIPHERAL BLOOD MONONUCLEAR CELLS MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product (Cryopreserved or Frozen PBMC, Cultured or Fresh PBMC and Peripheral Blood Mononuclear Cell Isolation & Viability Kits)
6.2.2. By Application (Immunology, Infectious Disease, Hematology and Others)
6.2.3. By Technique (Density Gradient Centrifugation Process and Leukapheresis)
6.2.4. By Source (Human and Animals)
6.2.5. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
6.2.6. By Company (2024)
6.3. Market Map
6.3.1. By Product
6.3.2. By Application
6.3.3. By Technique
6.3.4. By Source
6.3.5. By Region
7. NORTH AMERICA PERIPHERAL BLOOD MONONUCLEAR CELLS MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product
7.2.2. By Application
7.2.3. By Technique
7.2.4. By Source
7.2.5. By Country
7.3. North America: Country Analysis
7.3.1. United States Peripheral Blood Mononuclear Cells Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Product
7.3.1.2.2. By Application
7.3.1.2.3. By Technique
7.3.1.2.4. By Source
7.3.2. Canada Peripheral Blood Mononuclear Cells Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Product
7.3.2.2.2. By Application
7.3.2.2.3. By Technique
7.3.2.2.4. By Source
7.3.3. Mexico Peripheral Blood Mononuclear Cells Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Product
7.3.3.2.2. By Application
7.3.3.2.3. By Technique
7.3.3.2.4. By Source
8. EUROPE PERIPHERAL BLOOD MONONUCLEAR CELLS MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product
8.2.2. By Application
8.2.3. By Technique
8.2.4. By Source
8.2.5. By Country
8.3. Europe: Country Analysis
8.3.1. Germany Peripheral Blood Mononuclear Cells Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Product
8.3.1.2.2. By Application
8.3.1.2.3. By Technique
8.3.1.2.4. By Source
8.3.2. France Peripheral Blood Mononuclear Cells Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Product
8.3.2.2.2. By Application
8.3.2.2.3. By Technique
8.3.2.2.4. By Source
8.3.3. United Kingdom Peripheral Blood Mononuclear Cells Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Product
8.3.3.2.2. By Application
8.3.3.2.3. By Technique
8.3.3.2.4. By Source
8.3.4. Italy Peripheral Blood Mononuclear Cells Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Product
8.3.4.2.2. By Application
8.3.4.2.3. By Technique
8.3.4.2.4. By Source
8.3.5. Spain Peripheral Blood Mononuclear Cells Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Product
8.3.5.2.2. By Application
8.3.5.2.3. By Technique
8.3.5.2.4. By Source
9. ASIA-PACIFIC PERIPHERAL BLOOD MONONUCLEAR CELLS MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product
9.2.2. By Application
9.2.3. By Technique
9.2.4. By Source
9.2.5. By Country
9.3. Asia-Pacific: Country Analysis
9.3.1. China Peripheral Blood Mononuclear Cells Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Product
9.3.1.2.2. By Application
9.3.1.2.3. By Technique
9.3.1.2.4. By Source
9.3.2. Japan Peripheral Blood Mononuclear Cells Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Product
9.3.2.2.2. By Application
9.3.2.2.3. By Technique
9.3.2.2.4. By Source
9.3.3. India Peripheral Blood Mononuclear Cells Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Product
9.3.3.2.2. By Application
9.3.3.2.3. By Technique
9.3.3.2.4. By Source
9.3.4. South Korea Peripheral Blood Mononuclear Cells Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Product
9.3.4.2.2. By Application
9.3.4.2.3. By Technique
9.3.4.2.4. By Source
9.3.5. Australia Peripheral Blood Mononuclear Cells Market Outlook
9.3.5.1. Market Size & Forecast
9.3.5.1.1. By Value
9.3.5.2. Market Share & Forecast
9.3.5.2.1. By Product
9.3.5.2.2. By Application
9.3.5.2.3. By Technique
9.3.5.2.4. By Source
10. SOUTH AMERICA PERIPHERAL BLOOD MONONUCLEAR CELLS MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Product
10.2.2. By Application
10.2.3. By Technique
10.2.4. By Source
10.2.5. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Peripheral Blood Mononuclear Cells Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Product
10.3.1.2.2. By Application
10.3.1.2.3. By Technique
10.3.1.2.4. By Source
10.3.2. Argentina Peripheral Blood Mononuclear Cells Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Product
10.3.2.2.2. By Application
10.3.2.2.3. By Technique
10.3.2.2.4. By Source
10.3.3. Colombia Peripheral Blood Mononuclear Cells Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Product
10.3.3.2.2. By Application
10.3.3.2.3. By Technique
10.3.3.2.4. By Source
11. MIDDLE EAST AND AFRICA PERIPHERAL BLOOD MONONUCLEAR CELLS MARKET OUTLOOK
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Product
11.2.2. By Application
11.2.3. By Technique
11.2.4. By Source
11.2.5. By Country
11.3. MEA: Country Analysis
11.3.1. UAE Peripheral Blood Mononuclear Cells Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Product
11.3.1.2.2. By Application
11.3.1.2.3. By Technique
11.3.1.2.4. By Source
11.3.2. Saudi Arabia Peripheral Blood Mononuclear Cells Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Product
11.3.2.2.2. By Application
11.3.2.2.3. By Technique
11.3.2.2.4. By Source
11.3.3. South Africa Peripheral Blood Mononuclear Cells Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Product
11.3.3.2.2. By Application
11.3.3.2.3. By Technique
11.3.3.2.4. By Source
12. MARKET DYNAMICS
12.1. Drivers
12.2. Challenges
13. MARKET TRENDS & DEVELOPMENTS
13.1. Merger & Acquisition (If Any)
13.2. Product Launches (If Any)
13.3. Recent Developments
14. PORTERS FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products/Services
15. SWOT ANALYSIS: GLOBAL PERIPHERAL BLOOD MONONUCLEAR CELLS MARKET
16. CLINICAL TRIAL ANALYSIS
16.1. Ongoing Clinical Trials
16.2. Completed Clinical Trials
16.3. Terminated Clinical Trials
16.4. Breakdown of Pipeline, By Development Phase
16.5. Breakdown of Pipeline, By Status
16.6. Breakdown of Pipeline, By Study Type
16.7. Breakdown of Pipeline, By Region
16.8. Clinical Trials Heat Map
17. COMPETITIVE LANDSCAPE
17.1. Charles River Laboratories International, Inc.
17.1.1. Business Overview
17.1.2. Company Snapshot
17.1.3. Products & Services
17.1.4. Financials (As Reported)
17.1.5. Recent Developments
17.1.6. Key Personnel Details
17.1.7. SWOT Analysis
17.2. Lonza Group AG
17.3. Corning Inc.
17.4. Bio-Rad Laboratories Inc.
17.5. ABCAM
17.6. Biolegend Inc.
17.7. ZEN-Bio Inc.
17.8. DAPCEL, Inc.
17.9. Creative Bioarray
17.10. iXCells Biotechnologies USA, LLC
18. STRATEGIC RECOMMENDATIONS
19. ABOUT US & DISCLAIMER
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, and Trends
4. IMPACT OF COVID-19 ON GLOBAL PERIPHERAL BLOOD MONONUCLEAR CELLS MARKET
5. VOICE OF CUSTOMER
6. GLOBAL PERIPHERAL BLOOD MONONUCLEAR CELLS MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product (Cryopreserved or Frozen PBMC, Cultured or Fresh PBMC and Peripheral Blood Mononuclear Cell Isolation & Viability Kits)
6.2.2. By Application (Immunology, Infectious Disease, Hematology and Others)
6.2.3. By Technique (Density Gradient Centrifugation Process and Leukapheresis)
6.2.4. By Source (Human and Animals)
6.2.5. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
6.2.6. By Company (2024)
6.3. Market Map
6.3.1. By Product
6.3.2. By Application
6.3.3. By Technique
6.3.4. By Source
6.3.5. By Region
7. NORTH AMERICA PERIPHERAL BLOOD MONONUCLEAR CELLS MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product
7.2.2. By Application
7.2.3. By Technique
7.2.4. By Source
7.2.5. By Country
7.3. North America: Country Analysis
7.3.1. United States Peripheral Blood Mononuclear Cells Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Product
7.3.1.2.2. By Application
7.3.1.2.3. By Technique
7.3.1.2.4. By Source
7.3.2. Canada Peripheral Blood Mononuclear Cells Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Product
7.3.2.2.2. By Application
7.3.2.2.3. By Technique
7.3.2.2.4. By Source
7.3.3. Mexico Peripheral Blood Mononuclear Cells Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Product
7.3.3.2.2. By Application
7.3.3.2.3. By Technique
7.3.3.2.4. By Source
8. EUROPE PERIPHERAL BLOOD MONONUCLEAR CELLS MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product
8.2.2. By Application
8.2.3. By Technique
8.2.4. By Source
8.2.5. By Country
8.3. Europe: Country Analysis
8.3.1. Germany Peripheral Blood Mononuclear Cells Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Product
8.3.1.2.2. By Application
8.3.1.2.3. By Technique
8.3.1.2.4. By Source
8.3.2. France Peripheral Blood Mononuclear Cells Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Product
8.3.2.2.2. By Application
8.3.2.2.3. By Technique
8.3.2.2.4. By Source
8.3.3. United Kingdom Peripheral Blood Mononuclear Cells Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Product
8.3.3.2.2. By Application
8.3.3.2.3. By Technique
8.3.3.2.4. By Source
8.3.4. Italy Peripheral Blood Mononuclear Cells Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Product
8.3.4.2.2. By Application
8.3.4.2.3. By Technique
8.3.4.2.4. By Source
8.3.5. Spain Peripheral Blood Mononuclear Cells Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Product
8.3.5.2.2. By Application
8.3.5.2.3. By Technique
8.3.5.2.4. By Source
9. ASIA-PACIFIC PERIPHERAL BLOOD MONONUCLEAR CELLS MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product
9.2.2. By Application
9.2.3. By Technique
9.2.4. By Source
9.2.5. By Country
9.3. Asia-Pacific: Country Analysis
9.3.1. China Peripheral Blood Mononuclear Cells Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Product
9.3.1.2.2. By Application
9.3.1.2.3. By Technique
9.3.1.2.4. By Source
9.3.2. Japan Peripheral Blood Mononuclear Cells Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Product
9.3.2.2.2. By Application
9.3.2.2.3. By Technique
9.3.2.2.4. By Source
9.3.3. India Peripheral Blood Mononuclear Cells Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Product
9.3.3.2.2. By Application
9.3.3.2.3. By Technique
9.3.3.2.4. By Source
9.3.4. South Korea Peripheral Blood Mononuclear Cells Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Product
9.3.4.2.2. By Application
9.3.4.2.3. By Technique
9.3.4.2.4. By Source
9.3.5. Australia Peripheral Blood Mononuclear Cells Market Outlook
9.3.5.1. Market Size & Forecast
9.3.5.1.1. By Value
9.3.5.2. Market Share & Forecast
9.3.5.2.1. By Product
9.3.5.2.2. By Application
9.3.5.2.3. By Technique
9.3.5.2.4. By Source
10. SOUTH AMERICA PERIPHERAL BLOOD MONONUCLEAR CELLS MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Product
10.2.2. By Application
10.2.3. By Technique
10.2.4. By Source
10.2.5. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Peripheral Blood Mononuclear Cells Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Product
10.3.1.2.2. By Application
10.3.1.2.3. By Technique
10.3.1.2.4. By Source
10.3.2. Argentina Peripheral Blood Mononuclear Cells Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Product
10.3.2.2.2. By Application
10.3.2.2.3. By Technique
10.3.2.2.4. By Source
10.3.3. Colombia Peripheral Blood Mononuclear Cells Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Product
10.3.3.2.2. By Application
10.3.3.2.3. By Technique
10.3.3.2.4. By Source
11. MIDDLE EAST AND AFRICA PERIPHERAL BLOOD MONONUCLEAR CELLS MARKET OUTLOOK
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Product
11.2.2. By Application
11.2.3. By Technique
11.2.4. By Source
11.2.5. By Country
11.3. MEA: Country Analysis
11.3.1. UAE Peripheral Blood Mononuclear Cells Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Product
11.3.1.2.2. By Application
11.3.1.2.3. By Technique
11.3.1.2.4. By Source
11.3.2. Saudi Arabia Peripheral Blood Mononuclear Cells Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Product
11.3.2.2.2. By Application
11.3.2.2.3. By Technique
11.3.2.2.4. By Source
11.3.3. South Africa Peripheral Blood Mononuclear Cells Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Product
11.3.3.2.2. By Application
11.3.3.2.3. By Technique
11.3.3.2.4. By Source
12. MARKET DYNAMICS
12.1. Drivers
12.2. Challenges
13. MARKET TRENDS & DEVELOPMENTS
13.1. Merger & Acquisition (If Any)
13.2. Product Launches (If Any)
13.3. Recent Developments
14. PORTERS FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products/Services
15. SWOT ANALYSIS: GLOBAL PERIPHERAL BLOOD MONONUCLEAR CELLS MARKET
16. CLINICAL TRIAL ANALYSIS
16.1. Ongoing Clinical Trials
16.2. Completed Clinical Trials
16.3. Terminated Clinical Trials
16.4. Breakdown of Pipeline, By Development Phase
16.5. Breakdown of Pipeline, By Status
16.6. Breakdown of Pipeline, By Study Type
16.7. Breakdown of Pipeline, By Region
16.8. Clinical Trials Heat Map
17. COMPETITIVE LANDSCAPE
17.1. Charles River Laboratories International, Inc.
17.1.1. Business Overview
17.1.2. Company Snapshot
17.1.3. Products & Services
17.1.4. Financials (As Reported)
17.1.5. Recent Developments
17.1.6. Key Personnel Details
17.1.7. SWOT Analysis
17.2. Lonza Group AG
17.3. Corning Inc.
17.4. Bio-Rad Laboratories Inc.
17.5. ABCAM
17.6. Biolegend Inc.
17.7. ZEN-Bio Inc.
17.8. DAPCEL, Inc.
17.9. Creative Bioarray
17.10. iXCells Biotechnologies USA, LLC
18. STRATEGIC RECOMMENDATIONS
19. ABOUT US & DISCLAIMER
